HSBC Sells Singapore Life and Health Insurance Business to Allianz for S$2.7 Billion
Quick Look
- HSBC has agreed to sell its Singapore life and health insurance business, HSBC Life Singapore, to Germany’s Allianz for S$2.7 billion (US$2.08 billion).
- The deal, expected to finalize in H1 2027 pending regulatory approval, includes a 15-year bancassurance agreement and is projected to generate a US$1.8 billion pre-tax gain for HSBC.
AI-generated summary
Why It Matters
HSBC's insurance arm expanded in Singapore in 2022 by acquiring French rival AXA for US$575 million, consolidating over 600,000 active policies. This sale marks a reversal of that expansion strategy.
HSBC has agreed to sell its Singapore life and health insurance business to Germany’s Allianz for S$2.7 billion (US$2.08 billion), with the deal expected to be completed in the first half of 2027, HSBC Group announced on Friday morning before the start of trading.
The disposal is expected to generate a pre-tax gain of US$1.8 billion and boost HSBC’s common equity tier 1 ratio by up to 15 basis points, the bank said.
As part of the deal, HSBC Singapore will enter a 15-year exclusive bancassurance distribution agreement with Allianz, receiving an initial S$200 million cash payment for distributing insurance products to its retail and high-net-worth clients.
Completion remains subject to regulatory approval. If finalised, Allianz will own HSBC Life Singapore and retain all of its employees.
The sale marks a reversal of HSBC's approach to its Singapore insurance business. HSBC’s insurance arm expanded in Singapore in 2022 when it purchased French rival AXA for US$575 million, consolidated more than 600,000 active policies covering life and death, health and property in Singapore, the bank said in the 2021 acquisition announcement.
What to Watch
AI outlook — possibilities, not facts
The deal between HSBC and Allianz will be completed in the first half of 2027.
Likely · Within months
The deal will receive regulatory approval.
Likely · Within months
Open Questions
- What specific regulatory hurdles must be cleared?
- What are the long-term strategic implications for HSBC's other insurance businesses?
